Overview

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Ramucirumab